Skip to main content
main-content

01.10.2006 | Commentary | Ausgabe 5/2006

Breast Cancer Research 5/2006

Prevention of breast cancer using selective oestrogen receptor modulators (SERMs)

Zeitschrift:
Breast Cancer Research > Ausgabe 5/2006
Autor:
Trevor J Powles
Wichtige Hinweise

Competing interests

TJP has received honoraria for his role as a lecturer and advisor to Eli Lilly and Pfizer.

Abstract

Placebo controlled trials in over 25,000 women showed that tamoxifen reduced breast cancer risk by about 40% and osteoporotic fracture risk by about 32%. Similarly placebo controlled trials in nearly 18,000 women showed that raloxifene reduced breast cancer risk by 44–72% and osteoporotic fractures risk by 30–50%. A direct comparison of tamoxifen with raloxifene showed similar risk reduction for breast cancer and osteoporotic fractures with less toxicity for raloxifene.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 5/2006

Breast Cancer Research 5/2006 Zur Ausgabe